TP53 and diffuse large B-cell lymphoma: Previous studies have shown that TP53 mutation status plays a pivotal role in predicting outcome in patients with peripheral DLBCL treated with R-CHOP/CHOP-like chemotherapy: Patients with MUT-TP53 have a 2-fold higher relative risk of death compared to patients with WT-TP53, and patients with TP53 mutations that involved hotspot residues, and overlapping direct DNA contact residues of the DBD had a high mortality rate [51–53].